A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

@article{Stewart2013ARP,
  title={A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.},
  author={A Keith Stewart and Suzanne Trudel and Nizar Jacques Bahlis and Darrell White and Waleed Sabry and Andrew R. Belch and T. H. Reiman and Jean Roy and Chaim Shustik and Michael J. Kovacs and Morel Rubinger and Guy Cantin and Kevin W. Song and Kirsty A Tompkins and Deb C Marcellus and Martha Q. Lacy and Jonathan Sussman and Donna E. Reece and Michael Brundage and Erica L Harnett and Lois Shepherd and J. W. Chapman and Ralph M Meyer},
  journal={Blood},
  year={2013},
  volume={121 9},
  pages={1517-23}
}
We conducted a randomized, controlled trial comparing thalidomide-prednisone as maintenance therapy with observation in 332 patients who had undergone autologous stem cell transplantation with melphalan 200 mg/m2. The primary end point was overall survival (OS); secondary end points were myeloma-specific progression-free survival,progression-free survival, incidence of venous thromboembolism, and health-related quality of life (HRQoL). With a median follow-up of 4.1 years, no differences in OS… CONTINUE READING